Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multicenter, Extension Study to Evaluate the Long Term Safety of Intravenous CR845 in Hemodialysis Patients With Chronic Kidney Disease-Associated Pruritus

Trial Profile

An Open-Label, Multicenter, Extension Study to Evaluate the Long Term Safety of Intravenous CR845 in Hemodialysis Patients With Chronic Kidney Disease-Associated Pruritus

Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Jan 2019

At a glance

  • Drugs Difelikefalin (Primary)
  • Indications Pruritus
  • Focus Adverse reactions; Registrational
  • Sponsors Cara Therapeutics
  • Most Recent Events

    • 07 Jan 2019 According to a Cara Therapeutics media release, the company has enrolled more than 200 patients. Thus far, over 100 patients have completed at least six months of treatment, with approximately 40 percent of these through the one-year treatment period.
    • 14 Sep 2018 Planned End Date changed from 1 Oct 2018 to 1 Nov 2019.
    • 14 Sep 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Nov 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top